Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› London
Clinical trial register · United Kingdom · industry-sponsored

Clinical Trials in London, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 2878 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 04 Nov 2026, 03:15 UTC
2878
Studies in scope
industry-sponsored, all four open statuses
1384
Recruiting now
open to new participants
542
Lead sponsors
across recruiting studies
Top sites
London 98 Manchester 37 Cambridge 28 Glasgow 22 Bristol 18
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca139 Merck Sharp & Dohme LLC98 Hoffmann-La Roche83 Novartis Pharmaceuticals73 Janssen Research & Development, LLC71 Clear sponsor filter
Site city
London98 Manchester37 Cambridge28 Glasgow22 Bristol18
All 92 cities
Target enrolment
to

Trials with a site in London

98 of 2878 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Recruiting
Merck Sharp & Dohme LLC
Phase 3
876
London, Swansea
2026-05-04
Recruiting
Merck Sharp & Dohme LLC
Phase 3
590
Cambridge, London
2026-04-23
Recruiting
Merck Sharp & Dohme LLC
Phase 2
100
Cambridge, Bury, London, Huddersfield
2026-03-24
Recruiting
Merck Sharp & Dohme LLC
Phase 3
450
Glasgow, London, Manchester
2026-03-23
Recruiting
Merck Sharp & Dohme LLC
Phase 3
400
London, Portsmouth
2026-03-18
Recruiting
Merck Sharp & Dohme LLC
Phase 3
900
Bath, Cambridge, Leicester, London, Manchester
2026-02-16
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
55
London
2026-02-09
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,023
Edinburgh, Truro, London, Withington
2026-01-19
Recruiting
Merck Sharp & Dohme LLC
Phase 2
150
London, Manchester
2025-12-04
Active, closed
Merck Sharp & Dohme LLC
Phase 3
996
Bristol, Yate, London, Corby
2025-11-11
Active, closed
Merck Sharp & Dohme LLC
Phase 2
185
Harlow, Leeds, London
2025-10-08
Recruiting
Merck Sharp & Dohme LLC
Phase 3
675
Truro, London, Birmingham, Leicester
2025-10-08
Recruiting
Merck Sharp & Dohme LLC
Phase 2
250
East Sussex, Truro, London, Edinburgh, Birmingham, Manchester
2025-08-11
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,000
London, Leicester, Manchester
2025-07-21
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
140
Edinburgh, Glasgow, London, Cardiff, Manchester
2025-07-20
Recruiting
Merck Sharp & Dohme LLC
Phase 3
477
Birmingham, London, Oxford, Coventry, Cardiff, Manchester
2025-07-16
Recruiting
Merck Sharp & Dohme LLC
Phase 2
340
Aberdeen, Edinburgh, Southampton, London, Oxford, Bath, Birmingham
2025-07-16
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
360
Cambridge, London
2025-07-03
Recruiting
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
NCT06966700Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms
DrugsEpirubicin·Adriamycin·Xeloda·Sacituzumab tirumotecan
Merck Sharp & Dohme LLC
Phase 3
2,400
London, Dundee, Huddersfield, Colchester, Orpington, Nottingham, Blackpool, Leicester
2025-06-30
Active, closed
Merck Sharp & Dohme LLC
Phase 2
149
Dudley, London
2025-06-09
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,123
East Sussex, Cambridge, Glasgow, London, Edinburgh, Leicester, Maidstone, Manchester
2025-05-22
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,440
Cambridge, London, Exeter, Birmingham, Northwood, Sutton, Devon
2025-05-13
Active, closed
Merck Sharp & Dohme LLC
Phase 2
130
Cambridge, London, Glasgow
2025-05-12
Active, closed
Merck Sharp & Dohme LLC
Phase 2
440
London
2025-04-16
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
605
Brighton, Fulham, Sutton, London, Manchester
2025-04-15
Recruiting
Merck Sharp & Dohme LLC
Phase 2
594
Bristol, Aylesbury, Exeter, Plymouth, Middlesbrough, Lincoln, London, Oxford
2025-04-11
Recruiting
Merck Sharp & Dohme LLC
Phase 3
770
Cambridge, Edinburgh, Preston, London, Sutton, Birmingham, Leicester, Liverpool
2025-04-09
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,000
Truro, London, Nottingham, Taunton, Birmingham, Cardiff, Leeds
2025-03-16
Recruiting
A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)
NCT06833073Urinary Bladder Neoplasms, Non-Muscle Invasive Bladder Neoplasms, Carcinoma in Situ
DrugIntismeran autogene
Merck Sharp & Dohme LLC
Phase 2
308
Glasgow, London, Torquay
2025-03-11
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
327
London, Liverpool, Manchester
2025-02-27
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
181
London, Glasgow
2025-02-26
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
32
London
2024-12-20
Active, closed
Merck Sharp & Dohme LLC
Phase 2
120
Truro, London, Withington, Ipswich
2024-11-27
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,380
Prescot, London
2024-11-25
Recruiting
Merck Sharp & Dohme LLC
Phase 3
680
Bristol, London, Nottingham, Leeds, Leicester, Manchester, Metropolitan Borough of Wirral, Portsmouth
2024-10-21
Active, closed
Merck Sharp & Dohme LLC
Phase 2
66
Bodelwyddan, London, Oxford, Manchester
2024-10-14
Recruiting
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
NCT06395103B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, Burkitt Lymphoma, Neuroblastoma
DrugZilovertamab vedotin
Merck Sharp & Dohme LLC
Phase 1/2
90
Birmingham, Newcastle upon Tyne, London, Sutton, Cardiff
2024-08-16
Active, closed
Merck Sharp & Dohme LLC
Phase 3
3,000
London
2024-08-05
Active, closed
Merck Sharp & Dohme LLC
Phase 3
686
London, Sutton, Glasgow, Leeds, Manchester
2024-07-24
Active, closed
Merck Sharp & Dohme LLC
Phase 1/2
38
London
2024-07-17
Active, closed
Merck Sharp & Dohme LLC
Phase 3
300
Bodelwyddan, Gloucester, Lincoln, Boston, London, Newcastle upon Tyne, Newport
2024-07-16
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,530
Bristol, Hills Road, Truro, London, Edinburgh, Leeds
2024-06-24
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
220
London, Coventry
2024-06-20
Recruiting
Merck Sharp & Dohme LLC
Phase 3
851
Londonderry, Torquay, London, Nottingham
2024-06-10
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,200
Cambridge, Exeter, Doncaster, Huddersfield, London, Southampton, Oxford, Bristol
2024-06-05
Recruiting
A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)
NCT06351631Thrombocythemia, Essential, Primary Myelofibrosis, Myelofibrosis, Post-polycythemia Vera Myelofibrosis
DrugBomedemstat
Merck Sharp & Dohme LLC
Phase 3
400
London, Boston
2024-05-23
Active, closed
Merck Sharp & Dohme LLC
Phase 1/2
220
Cambridge, Glasgow, Preston, London, Birmingham
2024-05-20
Active, closed
Merck Sharp & Dohme LLC
Phase 3
473
Cambridge, Dundee, London, Manchester
2024-05-03
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,200
Londonderry, Truro, London, Blackpool, Nottingham
2024-04-14
Active, closed
Merck Sharp & Dohme LLC
Phase 2
272
Cambridge, Glasgow, London, Edinburgh, Manchester
2024-04-10
Recruiting
Merck Sharp & Dohme LLC
Phase 3
780
Cambridge, Northwood, London, Oxford, Newcastle upon Tyne
2024-04-03
Active, closed
Merck Sharp & Dohme LLC
Phase 1/2
230
Torquay, London, Glasgow, Manchester
2024-03-28
Active, closed
Merck Sharp & Dohme LLC
Phase 3
340
Cambridge, Gloucester, Lincoln, Boston, London, Gwent, Windsor, Manchester
2023-12-31
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,310
Cambridge, Truro, Glasgow, London, Manchester
2023-12-31
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,314
Cambridge, Derby, Torquay, Northwood, Truro, Glasgow, London, Oxford
2023-12-18
Recruiting
Merck Sharp & Dohme LLC
Phase 3
614
London, Portsmouth, Canterbury, Central Middlesbrough
2023-12-15
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,200
Bristol, Lancaster, London, Oxford, Newmarket, Windsor, Barnet, Leeds
2023-12-13
Active, closed
Merck Sharp & Dohme LLC
Phase 3
710
East Sussex, Derby, London, Truro, Glasgow, Manchester
2023-12-06
Active, closed
Merck Sharp & Dohme LLC
Phase 3
556
London, Sutton, Manchester, Metropolitan Borough of Wirral
2023-11-12
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,109
Bristol, Cambridge, Exeter, Doncaster, Huddersfield, London, Southampton, West Midlands
2023-10-25
Active, closed
Merck Sharp & Dohme LLC
Phase 3
14,550
Bristol, Exeter, Walsall, London, Newcastle upon Tyne, Clydebank, Romford, Corby
2023-10-09
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,089
Bristol, Cambridge, Cringleford, London, Edinburgh, Oxford, Leeds, Manchester
2023-07-19
Active, closed
Merck Sharp & Dohme LLC
Phase 1/2
390
London
2023-06-23
Recruiting
Merck Sharp & Dohme LLC
Phase 2/3
342
London, Newcastle upon Tyne
2023-05-31
Active, closed
Merck Sharp & Dohme LLC
Phase 3
641
East Sussex, Bristol, London, Crumpsall
2023-03-17
Active, closed
Merck Sharp & Dohme LLC
Phase 2
129
London, Sheffield
2023-03-16
Active, closed
Merck Sharp & Dohme LLC
Phase 3
537
Bristol, London, Manchester
2023-03-08
Active, closed
Merck Sharp & Dohme LLC
Phase 3
553
East Sussex, Crumpsall, London, Newcastle upon Tyne, Birmingham
2023-02-20
Active, closed
Merck Sharp & Dohme LLC
Phase 3
514
Bristol, Birmingham, Liverpool, London, Cardiff, Reading
2023-02-17
Active, closed
Merck Sharp & Dohme LLC
Phase 3
614
Leicester, London, Metropolitan Borough of Wirral
2023-02-06
Recruiting
Merck Sharp & Dohme LLC
Phase 2
42
London
2023-01-19
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
48
London
2022-11-16
Active, closed
A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)
NCT05458297Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Richter Transformation Lymphoma
DrugsZilovertamab vedotin·Nemtabrutinib
Merck Sharp & Dohme LLC
Phase 2
189
Truro, London, Oxford, Manchester
2022-07-21
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,800
London, Nottingham, Glasgow, Manchester, Swansea
2022-03-15
Active, closed
Merck Sharp & Dohme LLC
Phase 3
280
Manchester, Glasgow, London
2022-02-03
Active, closed
Merck Sharp & Dohme LLC
Phase 3
643
East Sussex, Cambridge, Truro, Kendal, Dundee, Leicester, London, Cardiff
2021-12-13
Active, closed
Merck Sharp & Dohme LLC
Phase 2
60
London
2021-11-02
Active, closed
Merck Sharp & Dohme LLC
Phase 3
2,000
East Sussex, Bristol, London, Manchester
2021-09-15
Recruiting
Merck Sharp & Dohme LLC
Phase 2
355
Cambridge, London, Glasgow
2021-08-12
Active, closed
Merck Sharp & Dohme LLC
Phase 3
342
Truro, Leicester, London, Manchester, Blackpool, Londonderry
2021-06-18
Active, closed
Merck Sharp & Dohme LLC
Phase 3
815
Cambridge, Glasgow, London, Newcastle upon Tyne, Sheffield
2021-05-12
Active, closed
Merck Sharp & Dohme LLC
Phase 3
808
Torquay, London
2021-04-21
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,688
Cambridge, London, Northwood
2021-04-14
Recruiting
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
NCT04728893Hematologic Malignancies, Waldenstroms Macroglobulinaemia, Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukaemia
DrugNemtabrutinib
Merck Sharp & Dohme LLC
Phase 2
490
Bristol, Nottingham, Windsor, London, Oxford, Newmarket, Sutton, Manchester
2021-04-05
Active, closed
Merck Sharp & Dohme LLC
Phase 3
747
Aberdeen, Bath, Nottingham, Southend, London, Northwood, Taunton, Swansea
2021-02-25
Active, closed
Merck Sharp & Dohme LLC
Phase 3
990
Bristol, Cottingham, Glasgow, London, Sutton, Leicester, Manchester
2021-01-10
Active, closed
Merck Sharp & Dohme LLC
Phase 3
672
Aberdeen, Dundee, Taunton, London, Manchester
2020-12-08
Active, closed
Merck Sharp & Dohme LLC
Phase 3
870
Sheffield, London, London-Camden, Southampton, Leeds, Manchester
2020-07-06
Active, closed
Merck Sharp & Dohme LLC
Phase 3
520
Rhyl, Torquay, Preston, London, Nottingham, Darlington
2020-05-19
Active, closed
Merck Sharp & Dohme LLC
Phase 3
755
Cambridge, Edinburgh, Glasgow, London, Sutton, Gillingham, Manchester
2020-02-27
Active, closed
Merck Sharp & Dohme LLC
Phase 3
595
Walsall, Canterbury, Middlesbrough, London, Stevenage, Edinburgh, Metropolitan Borough of Wirral, Truro
2019-07-24
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,240
Bristol, Nottingham, Colchester, London, Solihull, Truro
2018-12-27
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,397
Inverness, London
2018-12-24
Active, closed
Merck Sharp & Dohme LLC
Phase 3
714
Cambridge, Cottingham-Hull, London, Sheffield
2018-12-17
Active, closed
Merck Sharp & Dohme LLC
Phase 3
976
Cambridge, London, Sutton, Manchester
2018-09-12
Active, closed
Merck Sharp & Dohme LLC
Phase 3
797
Leicester, Metropolitan Borough of Wirral, London, Sutton, Nottingham, Birmingham, Newcastle upon Tyne, Plymouth
2018-04-24
Active, closed
Merck Sharp & Dohme LLC
Phase 2
340
London
2018-04-09
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
370
London
2015-03-19
Rows per page Showing 1–98 of 98
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 5 November 2026. https://priyalifescience.com/clinical-trials-uk/city/london

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the UK and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,878 studies in total at the last sync on 04 Nov 2026, 03:15 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 98 of those studies with a site in London that also match the filters currently applied.

How many clinical trials are recruiting in London?

47 of the 98 studies on this page are recruiting new participants as of the 04 Nov 2026, 03:15 UTC sync. A further 0 have not yet opened recruitment, 51 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (London), 98 studies
PhaseStudiesRecruitingShare
Phase 3622663.3%
Phase 220920.4%
Phase 1/2151115.3%
Phase 2/3111%

Most active sponsors

Lead sponsors with the most studies (London)
Lead sponsorStudiesRecruiting
Merck Sharp & Dohme LLC9847
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.